Plaque Psoriasis in ChildrenPlaque Psoriasis in Adolescents
Investigational drug(s) / intervention(s)
RSS0393 Ointment
RSS0393 Ointment: RSS0393 ointment.
Study summary
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.
Eligibility
Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥ 6 years old and \< 18 years old at screening.
2. History of plaque psoriasis ≥ 3 months.
3. The subjects and their parents or legal guardians voluntarily signed informed consent before any study-related procedures began.
Exclusion Criteria:
1. Diagnosis of psoriasis other than plaque at screening.
2. Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study.
3. Subjects with any other persistent active autoimmune disease.
4. Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline.
Primary outcome measure(s)
Adverse events (AEs). — About 4 weeks.
Trial sites (1)
Facility
City
Region
Status
Beijing Children's Hospital, Capital Medical University
Beijing
Beijing Municipality
More Jiangsu HengRui Medicine Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.